Loading company…
Wuhan biotech developing AAV-platform drugs for ophthalmic diseases, including Leber's hereditary optic neuropathy.
Based in Wuhan, China, and established in 2016, Neurophth develops new drugs for eye diseases on an AAV platform, with more than 10 pipeline products. Its NFS-01 and NFS-02 products target Leber's hereditary optic neuropathy, NFS-04 targets optic neuropathy injury and NFS-05 targets dominantly inherited optic atrophy. The company raised CNY 400 million in Series B funding in 2021 and about CNY 700 million in Series C+ funding in August 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in